CD38 and plasma cell myeloma: A further analysis was triggered when our GMMG-study group planned the CONCEPT trial (EudraCT 2016-000432-17) for upfront treatment of previously untreated high-risk myeloma patients [defined by the presence of t(4;14), del17p13, or >3 copies of 1q21 and ISS-stage II or III (19)] with addition of the anti-CD38-antibody isatuximab to intensified treatment.